Novo Nordisk A/S (NVO): Today's Featured Drugs Winner
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.2%. By the end of trading, Novo Nordisk A/S rose $2.04 (1.2%) to $167.85 on light volume. Throughout the day, 173,630 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 304,300 shares. The stock ranged in a price between $167.00-$168.13 after having opened the day at $167.61 as compared to the previous trading day's close of $165.81. Other companies within the Drugs industry that increased today were:
Senesco Technologies
(
SNTI
), up 56.1%,
(
), up 49.7%,
(
), up 24.7% and
(
), up 16.3%.
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $91.1 billion and is part of the health care sector. Shares are up 1.6% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Novo Nordisk A/S
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Novo Nordisk A/S Ratings Report.
On the negative front,
(
), down 37.2%,
IntelliPharmaCeutics International
(
), down 20.4%,
(
), down 16.9% and
(
), down 16.1% , were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null